Related references
Note: Only part of the references are listed.Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs
Amina Ait-Ammar et al.
FRONTIERS IN MICROBIOLOGY (2020)
Two's a Company, Three's a Crowd: A Review of Initiating or Switching to a Two-Drug Antiretroviral Regimen in Treatment-Naive and Treatment-Experienced Patients Living with HIV-1
Melissa Badowski et al.
INFECTIOUS DISEASES AND THERAPY (2020)
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A
Ilaria Vicenti et al.
JOURNAL OF CLINICAL VIROLOGY (2019)
Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs
Ivan Sadowski et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2019)
Stable integrant-specific differences in bimodal HIV-1 expression patterns revealed by high-throughput analysis
David F. Read et al.
PLOS PATHOGENS (2019)
Novel Latency Reversal Agents for HIV-1 Cure
Adam M. Spivak et al.
ANNUAL REVIEW OF MEDICINE, VOL 69 (2018)
Blood biomarkers of expressed and inducible HIV-1
Anthony R. Cillo et al.
AIDS (2018)
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood
Ilaria Vicenti et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2018)
Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4+ T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy
Nadia Madrid-Elena et al.
JOURNAL OF VIROLOGY (2018)
Wake me up before you go: a strategy to reduce the latent HIV reservoir
Nicolas Chomont et al.
AIDS (2018)
Novel assay reveals a large, inducible, replication-competent HIV-1 reservoir in resting CD4+ T cells
Anwesha Sanyal et al.
NATURE MEDICINE (2017)
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial
Barbara Rossetti et al.
PLOS ONE (2017)
The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
Maria Rosa Lopez-Huertas et al.
SCIENTIFIC REPORTS (2017)
Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals
Sergio Serrano-Villar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder
Thomas M. Gates et al.
AIDS (2016)
Differential CD4+ cell count increase and CD4+: CD8+ ratio normalization with maraviroc compared with tenofovir
Ellen S. Chan et al.
AIDS (2016)
Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial
Christine Katlama et al.
AIDS (2016)
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study
Sarah Lilian Pett et al.
CLINICAL INFECTIOUS DISEASES (2016)
Latency reversal and viral clearance to cure HIV-1
David M. Margolis et al.
SCIENCE (2016)
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery
Anthony R. Cillo et al.
AIDS (2015)
Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial
M. Ripa et al.
CLINICAL MICROBIOLOGY AND INFECTION (2015)
Maraviroc: a review of its use in HIV infection and beyond
Shawna M. Woollard et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction
Mario Ostrowski et al.
OPEN FORUM INFECTIOUS DISEASES (2015)
In Vitro Immunological Effects of Blocking CCR5 on T Cells
Jing Yuan et al.
INFLAMMATION (2015)
Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection
Maria C. Puertas et al.
AIDS (2014)
A Randomized Open-Label Study of 3-Versus 5-Drug Combination Antiretroviral Therapy in Newly HIV-1-Infected Individuals
Martin Markowitz et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2014)
Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND)
Lishomwa C. Ndhlovu et al.
JOURNAL OF NEUROVIROLOGY (2014)
Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of HIV-1-Infected CD4 T Cells
Maria J. Buzon et al.
JOURNAL OF VIROLOGY (2014)
Highlights from the 2014 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the end of the HIV pandemic
Alain Lafeuillade et al.
AIDS RESEARCH AND THERAPY (2014)
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial
Peter W. Hunt et al.
BLOOD (2013)
In vitro effects of the CCR5 inhibitor maraviroc on human T cell function
H. Arberas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial
Stefano Rusconi et al.
PLOS ONE (2013)
Rapid Quantification of the Latent Reservoir for HIV-1 Using a Viral Outgrowth Assay
Gregory M. Laird et al.
PLOS PATHOGENS (2013)
Immune recovery and T cell subset analysis during effective treatment with maraviroc
Francesca Cossarini et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
A Pilot Trial of Adding Maraviroc to Suppressive Antiretroviral Therapy for Suboptimal CD4+ T-Cell Recovery Despite Sustained Virologic Suppression: ACTG A5256
Timothy J. Wilkin et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected
Carolina Gutierrez et al.
PLOS ONE (2011)
CD4+ T-Cell Restoration After 48 Weeks in the Maraviroc Treatment-Experienced Trials MOTIVATE 1 and 2
David M. Asmuth et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients
Nicholas Funderburg et al.
PLOS ONE (2010)
CCR5 antagonism in HIV infection: ways, effects, and side effects
Pierre Corbeau et al.
AIDS (2009)
Real-time PCR quantitation of hepatitis B virus total DNA and covalently closed circular DNA in peripheral blood mononuclear cells from hepatitis B virus-infected patients
A. A. Mazet-Wagner et al.
JOURNAL OF VIROLOGICAL METHODS (2006)
Biology of CCR5 and its role in HIV infection and treatment
Michael M. Lederman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Increased expression of TLR3 in lymph nodes during simian immunodeficiency virus infection: Implications for inflammation and immunodeficiency
SK Sanghavi et al.
JOURNAL OF IMMUNOLOGY (2005)
Share Paper
